# Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)

Study · id `cardio:ct-nct01951638` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01951638](<https://clinicaltrials.gov/study/NCT01951638>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01951638

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 477 participants.

## Technical summary

Registry record NCT01951638. Randomized; quadruple masking; primary purpose treatment. Start 2013-11-06 (actual); primary completion 2015-08-18 (actual). Results posted on 2021-02-12.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 477 participants (enrolled count; ClinicalTrials.gov record NCT01951638, source copy `cardio:ctgov-nct01951638-2021-03-16`, retrieved 2026-10-26)
- Started: 2013-11-06 (actual) (ClinicalTrials.gov record NCT01951638, source copy `cardio:ctgov-nct01951638-2021-03-16`, retrieved 2026-10-26)
- Primary completion: 2015-08-18 (actual) (ClinicalTrials.gov record NCT01951638, source copy `cardio:ctgov-nct01951638-2021-03-16`, retrieved 2026-10-26)
- Completion: 2015-09-16 (actual) (ClinicalTrials.gov record NCT01951638, source copy `cardio:ctgov-nct01951638-2021-03-16`, retrieved 2026-10-26)
- Results first posted: 2021-02-12 (ClinicalTrials.gov record NCT01951638, source copy `cardio:ctgov-nct01951638-2021-03-16`, retrieved 2026-10-26)
- Countries: United States; Australia; Austria; Belgium; Bulgaria; Canada; Czechia; Denmark; France; Germany; Greece; Hungary; Israel; Italy; Japan; Netherlands; Poland; Portugal; Singapore; South Korea; Spain; Sweden; Switzerland; Taiwan; United Kingdom (ClinicalTrials.gov record NCT01951638, source copy `cardio:ctgov-nct01951638-2021-03-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01951638-2021-03-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
- Condition: Heart Failure
- Intervention (Drug): Vericiguat (BAY1021189) (1.25 mg)
- Intervention (Drug): Vericiguat (BAY1021189) (5 mg)
- Intervention (Drug): Placebo
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

## Provenance

Content hash: 399bfe5cd6e2a2960b4937189c1f1b3215ca9750658d421e9fd259a503bdac41
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
